Inflammatory biomarkers have a prognostic role in patients with metastatic castration‐resistant prostate cancer treated with Lutetium‐177–PSMA‐617Margo B. Gerke, Mehmet Asım Bilen, Jacob E. Berchuck et al.|Cancer|2026Cited by 2
Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibitionBrandon Wummer, Jacqueline T. Brown, Michael W. Schwartz et al.|Frontiers in Oncology|2025Cited by 1
Novel risk scoring system for patients with metastatic castration-resistant prostate cancer treated with lutetium-177–PSMA-617Margo B. Gerke, Mehmet Asım Bilen, Angelo Marra et al.|The Oncologist|2026Cited by 0